

Registered & Corporate Office:

Office No.: 301, 3rd Floor, Konark Icon, Mundhwa - Kharadi Rd,
Kirtane Baugh, Magarpatta, Hadapsar, Pune - 411028
Email: enquiry@cian.co, cianhealthcare@yahoo.co.in
Web: www.cian.co

Factory:

Kh. No.: 248, Village Sisona, Bhagwanpur, Roorkee, Haridwar,
Pin - 247 661. Uttarakhand, Tel.: 1332 235352

CIN: L24233PN2003PLC017563

Ref. No.: CIAN/BSE/2025-26/17

Wednesday, March 11, 2026

To,
The Manager-Listing,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400 001

Scrip Code: 542678

Symbol: CHCL

ISIN: INE05BN01019

- Subject:**
- i. Disclosure made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") by Cian Healthcare Limited ("Company"); and
 - ii. Update on the receipt of the below-mentioned approvals from the BSE Limited ("Stock Exchange" or "BSE") pursuant to the approved Resolution Plan read with the Order of the Hon'ble National Company Law Tribunal ("NCLT") dated December 18, 2025 ("NCLT Order").
 - a. In-principle approval for the issuance of 2,37,50,000 (Two Crores Thirty-Seven Lakhs Fifty Thousand) fully paid-up equity shares at a face value of INR 10/- (Indian Rupees Ten Only) each, to the prospective promoters; and
 - b. listing approval for 12,50,000 (Twelve Lakhs Fifty Thousand) fully paid-up equity shares at a face value of INR 10/- (Indian Rupees Ten Only) each to the public shareholders.

- Reference:**
- i. Disclosure dated December 19, 2025, in relation to the approval of the Resolution Plan by the Hon'ble National Company Law Tribunal, Bench-VI, Mumbai ("NCLT") vide its order dated December 18, 2025 ("NCLT Order"), as submitted by the Successful Resolution Applicant ("SRA"), namely Mr. Pradeep Kumar Jain, under the relevant provisions of the Insolvency and Bankruptcy Code, 2016 ("Code") and
 - ii. Outcome of the meetings (CIAN/RPIC/2025-26/02) and (CIAN/RPIC/2025-26/04) of the Resolution Plan Implementation Committee ("Implementation Committee") held on January 09, 2026, and January 23, 2026, respectively.



Registered & Corporate Office:

Office No.: 301, 3rd Floor, Konark Icon, Mundhwa - Kharadi Rd,
Kirtane Baugh, Magarpatta, Hadapsar, Pune - 411028
Email: enquiry@cian.co, cianhealthcare@yahoo.co.in
Web: www.cian.co

Factory:

Kh. No.: 248, Village Sisona, Bhagwanpur, Roorkee, Haridwar,
Pin - 247 661. Uttarakhand, Tel.: 1332 235352

CIN: L24233PN2003PLC017563

Dear Sir/Ma'am,

In compliance with the relevant provisions of Regulation 30 read with Schedule III, and other applicable provisions of the Listing Regulations, along with the provisions of SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/1/3762/2026 dated January 30, 2026 ("**SEBI Circular**"), and in accordance with the relevant provisions of the NCLT Order read with the Resolution Plan approved therein and such other applicable laws and regulations, and with reference to the captioned subject, the Company hereby inform the receipt of the approvals from the Stock Exchange dated March 10, 2026, which are enumerated hereunder:

- a. **In-principle approval for the issuance of 2,37,50,000 (Two Crores Thirty-Seven Lakhs Fifty Thousand) fully paid-up equity shares at a face value of INR 10/- (Indian Rupees Ten Only) each, to the prospective promoters; and**

The Company has received the in-principle approval from BSE for the issuance of 2,37,50,000 (Two Crores Thirty-Seven Lakhs Fifty Thousand) fully paid-up equity shares having a face value of INR 10/- (Indian Rupees Ten Only) each to the below-mentioned prospective promoters, in accordance with the NCLT Order read with the Resolution Plan approved therein:

| S. No. | Name of the Prospective Promoters | Total No. of shares | Shareholding Percentage (%) |
|--------------|-----------------------------------|---------------------|-----------------------------|
| 1. | Ananta Medicare Limited | 1,37,50,000 | 55 |
| 2. | Mr. Rajesh Jain | 52,50,000 | 21 |
| 3. | Mr. Pradeep Kumar Jain | 47,50,000 | 19 |
| Total | | 2,37,50,000 | 95 |

The Company shall proceed with the allotment of the aforesaid equity shares upon the completion of the applicable compliance requirements and fulfilment of such other conditions as may be stipulated in the approval letter issued by BSE. The equity shares proposed to be allotted shall rank *pari-passu* (including dividend and voting rights), with the existing equity shares held by the public shareholders of the Company.

A copy of the In-principle Approval letter received from BSE is attached herewith as **Annexure-A**.

- b. **listing approval for 12,50,000 (Twelve Lakhs Fifty Thousand) fully paid-up equity shares at a face value of INR 10/- (Indian Rupees Ten Only) each, to the public shareholders.**

The Company has received the listing approval from BSE for 12,50,000 (Twelve Lakhs Fifty Thousand) fully paid-up equity shares having a face value of INR 10/- (Indian Rupees Ten Only) each, which were allotted in the Implementation Committee meeting (CIAN/RPIC/2025-26/04) held on January 23, 2026, in accordance with the provisions of the NCLT Order read with the Resolution Plan approved therein.

The Company shall proceed with the completion of the requisite trading formalities with the Stock Exchange in respect of the aforesaid equity shares and shall undertake necessary actions for crediting the said shares to the demat accounts of the respective public shareholders, subject to the conditions specified in the approval letter in relation to listing and other applicable statutory and regulatory requirements.

Registered & Corporate Office:

Office No.: 301, 3rd Floor, Konark Icon, Mundhwa - Kharadi Rd,
Kirtane Baugh, Magarpatta, Hadapsar, Pune - 411028
Email: enquiry@cian.co, cianhealthcare@yahoo.co.in
Web: www.cian.co

Factory:

Kh. No.: 248, Village Sisona, Bhagwanpur, Roorkee, Haridwar,
Pin - 247 661. Uttarakhand, Tel.: 1332 235352

CIN: L24233PN2003PLC017563

A copy of the listing approval letter received from BSE is attached herewith as **Annexure-B**.

We shall continue to keep all stakeholders and regulatory authorities abreast of further material developments in this regard.

Kindly take the above information on record and oblige.

Thanking you,
For Cian Healthcare Limited

Rajesh Jain
Non-Executive Director
DIN: 02066848



DSC/PREF/AK/1119/2025-26

March 10, 2026

To,
The Company Secretary,
Cian Healthcare Ltd.
Milkat No. 3339, Block No.1,
C.S.No.227 /2 + 3A, From South Side,
Harpale Park, Opp Berger Paint,
Phursungi, Pune - 412308

Re: 'In-principle' approval under Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

Dear Sir/Madam,

We refer to your application seeking our **“In-principle approval for the issue of 2,37,50,000 equity shares of Rs. 10/- to the successful resolution applicants and/ or its Affiliates (new promoters)”**

The Exchange hereby grants its ‘in-principle’ approval for the aforesaid issue. This ‘in-principle’ approval should not be construed as our approval for listing of aforesaid security, and you are required to duly and separately comply with the requirements in respect thereof.

You are advised to ensure that the issue and allotment of securities is strictly in accordance with the provisions of the Companies Act, 2013, Securities Contracts (Regulation) Act, 1956, the Securities and Exchange Board of India Act, 1992, the Depositories Act, 1996 including the rules, regulations, guidelines, etc. made there under, Chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (ICDR Regulations), the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 (LODR Regulations) and the Listing Agreement signed with us. In addition, you shall also obtain such statutory and other approvals as are required for the purpose. On allotment of securities pursuant to this ‘in principle’ approval you are required to make a listing application without delay, with applicable fees, in terms of Regulation 14 of the LODR Regulations and comply with the post issue formalities.

Listing application and the checklist for post issue listing formalities can be downloaded from the link: <https://www.bseindia.com/static/about/downloads.aspx>. Further, it

should be noted by Depositories and the Company that in case of allotment of Convertible Securities, there would be automatic release of excess lock-in period of Pre-

Preferential Holding of allottees by Depositories in compliance with SEBI(ICDR) Regulations,2018 without requirement of any NOC by the Exchange.

In addition to above, the company should note that as per Schedule XIX – Para (2) of ICDR Regulations and as specified in SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023, “the issuer or the issuing company, as the case may be, shall, make an application

for listing, **within twenty days** from the date of allotment, to one or more recognized stock exchange(s)” along with the documents specified by stock exchange(s) from time to time. Any Non-compliance with the above requirement will attract, the fine as mentioned in SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023.

The Exchange reserves its right to withdraw this ‘in-principle’ approval at any stage if the information submitted to the Exchange is found to be incomplete/ incorrect/ misleading/ false or if it contravenes any Rules, Bye-laws and Regulations of the Exchange, LODR Regulations, ICDR Regulations and Guidelines/ Regulations issued by any statutory authorities etc.

Yours faithfully,



Marian Dsouza
Assistant Vice President



Abhishek Kadlak
Deputy Manager

DCS/AMAL/AK/R37-IBC/1121/2025-26

March 10, 2026

The Company Secretary
Cian Healthcare Ltd
Milkat No. 3339,
Block No.1, C.S.No.227 /2 + 3A,
From South Side, Harpale Park,
Opp Berger Paint, Phursungi,s
Pune, Maharashtra, 412308

Dear Sir/Madam,

Subject: Listing of 12,50,000 equity shares of Rs. 10/- each pursuant to Resolution Plan approved by Hon'ble NCLT, Mumbai Bench vide order dated December 18, 2025

We are in receipt of your application seeking Exchange's listing approval for the listing of following securities pursuant to resolution plan approved by Hon'ble NCLT, Mumbai Bench vide order dated December 18, 2025.

- 12,50,000 equity shares of Rs. 10/- each allotted pursuant to reduction of capital through approved resolution plan bearing distinctive no. from 01-12,50,000.

In view of above, the Exchange is pleased to grant you the listing approval for above mentioned 12,50,000 equity shares of Rs. 10/- each.

You are advised to submit the following documents while seeking trading permission from the Exchange:

- a) Scanned Copy of covering letter
- b) Listing approval obtained from National Stock Exchange, if applicable.
- c) ISIN activation letters from depositories.
- d) Auditor's certificate for determining the Book Value per shares considering the latest financials.
- e) Confirmation letters from CDSL and / or NSDL about crediting the above-mentioned shares to the respective beneficiaries account.
- f) Lock-in confirmation from depositories, as per SEBI (ICDR) Regulations, 2018
- g) Latest Shareholding Pattern as per the format prescribed under Regulation 31 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 in PDF as well as XBRL format (XBRL to be submitted through listing centre and confirmation to be provided for uploading the XBRL)-
 - 1.Pre-arrangement shareholding pattern
 - 2.Post arrangement shareholding pattern
- h) Old and new distinctive numbers
- i) Details of payment of the outstanding dues, if any
- j) Details of payment of SOP fines, If any

For BSE Limited
Yours faithfully,



Marian Dsouza
Assistant Vice President



Abhishek Kadlak
Deputy Manager